Rapport sells stock 24% below market to fund its drug through 2029

Rapport calls itself a clinical-stage biotechnology company that develops small-molecule precision medicines, and it is based in Boston and San Diego.¹ It was formed in February 2022 with founding support from Third Rock Ventures and Johnson & Johnson's venture arm.² Its lead drug, RAP-219, acts on a brain receptor called AMPA, and the company is testing it in focal onset seizures, primary generalized tonic-clonic seizures and bipolar mania.³ Rapport has no approved products and no product sales.⁴ All of its revenue so far is a $20.0 million upfront fee from Tenacia, which licensed the drug for Greater China.⁵ Its 10-Q says the business is highly dependent on RAP-219 for focal onset seizures, and that it will need more money to keep operating.⁶

Epilepsy is the main prize. Rapport puts the branded epilepsy drug market at about $2.8 billion in 2022, growing to about $3.6 billion by 2028.¹ In September 2025 it reported that a small Phase 2a trial in drug-resistant focal onset seizures met its primary and secondary goals, and two pivotal Phase 3 trials, FOCUS 1 and FOCUS 2, are now enrolling.²

Before the raise, Rapport lost $56.6 million in the second quarter of 2026 and used $41.5 million of cash in operations.¹ It ended June with $436.1 million of cash, cash equivalents and short-term investments and no borrowed money.² Its 10-Q reports no material legal proceedings.³

Venture firm Third Rock Ventures V owned 6,280,525 shares, about 13.1%, and has named members of the board.¹ Capital International Investors reported 6.1% and Cormorant reported 5.56%, both as passive holders.² Chief executive Abraham Ceesay has sold steadily under a trading plan adopted in March 2026, including 28,958 shares in one August sale for $1,390,403.89, and he sold 2,210 more at $29.1618 on October 21, 2026, leaving him 450,035 shares.³

The stock had slid hard before this deal. It closed at $42.74 on September 15, 2026 and at $25.31 on October 26, a drop of about 41%, while the XBI biotech fund fell about 2% over the same days.

The stock sale has two parts. Underwriters led by Morgan Stanley, Leerink Partners and Evercore ISI are buying 8,333,334 shares at $21.00 and pre-funded warrants on 1,190,476 more shares at $20.999, for about $200.0 million.¹ A pre-funded warrant is a share paid for almost in full today; it never expires, and the buyer takes the stock later by paying $0.001 a share.² Separately, one investor agreed to buy 1,428,571 shares at the same $21.00 in a private sale, which closes only if the public stock sale closes.³ Rapport must register those shares so the investor can resell them.⁴ Underwriters also hold 30-day options to buy about $30.0 million more stock and $22.5 million more notes.⁵

The notes are $150 million of senior unsecured debt paying 2.25% a year and due December 1, 2032.¹ Each $1,000 note converts into 37.3483 shares, a conversion price of about $26.78.² That is 27.50% above the $21.00 stock price but below the $27.54 close just before pricing, so the notes would already be worth converting if the stock got back to its pre-deal level.³

The final term sheet changed the notes from the draft prospectus.¹ Rapport dropped the conditions on conversion, so holders can convert at any time until just before maturity, and it fixed settlement in shares only.² It also added a blocker that stops any holder from converting past 19.99% of the shares.³ Share settlement keeps cash in the company when notes convert, but every conversion adds shares, and any notes not converted must be repaid in cash at maturity.⁴ Rapport can call the notes only from December 6, 2030, only 60 days after topline results from its pivotal epilepsy and bipolar trials, and only if the stock trades at 130% of the conversion price, about $34.81, for 20 of 30 trading days.⁵ After a defined fundamental change such as a takeover, holders can demand 100% of face value in cash, and the notes prospectus warns Rapport may not have enough money to pay.⁶ The notes prospectus also expects many note buyers to hedge by selling the stock short, which can weigh on the share price while the deal settles.⁷

Here is each side of the money. Stock buyers pay $21.00 a share for common stock that has never paid a dividend, and Rapport pays underwriters $1.26 a share, a 3.0% discount on the notes and a 6.0% fee on the private sale.¹ After those costs it expects about $215.7 million from the stock and private sale and about $145.0 million from the notes, or $360.7 million in all.² It says the money goes mainly to RAP-219 trials, and it has no deal in hand to buy or license anything else.³ Note buyers get 2.25% a year, about $3.4 million in interest, plus the right to swap into shares, while Rapport gets cheap money now and pays in stock later if the price rises.⁴

Rapport had $436.1 million of cash, cash equivalents and short-term investments at June 30, 2026, and it estimates about $395.0 million at September 30.¹ That implies about $41.1 million used in the third quarter, close to the $41.5 million operating cash outflow of the second quarter.² The September figure is preliminary, the auditor has not reviewed it, and actual third-quarter results will not be out until after the offering.³ Adding the net proceeds gives about $755.7 million before fourth-quarter spending, against the $150 million of new notes and no other borrowed money, or about $605.7 million of net cash.⁴ Debt-to-earnings ratios do not apply because Rapport loses money, and the note interest of about $3.4 million a year is less than the $4.2 million of interest income it earned in the second quarter alone.⁵

The runway barely moved. Before the raise, Rapport said June cash would last into the second half of 2029, and with $360.7 million more it now says through the end of 2029.¹ Our reading is that the company expects spending to climb steeply as three late-stage programs run at once, and it warns the estimate rests on assumptions that may prove wrong.²

The second quarter's $41.5 million of operating cash use was most of its $56.6 million net loss, so the losses are largely cash, not paper charges.¹ In the first half of 2026 Rapport lost $76.5 million, a loss softened by the one-time $20.0 million Tenacia fee and including $14.2 million of stock pay, which costs no cash.²

Rapport had 47,978,286 shares outstanding on August 3, 2026, so its market value at the $27.54 close was about $1.32 billion and the $380 million raised equals about 29% of it.¹ The new stock and warrants add about 11.0 million shares, about 23% more.² The notes add 5.6 million shares at the starting rate, or up to 7.1 million under make-whole rules that raise the rate after certain corporate events, and with the new stock that is about 34.5% more shares.³ Options on 8,030,456 shares, at an average exercise price of $16.43, sit on top, so a fully diluted count is near 72.6 million.⁴ Rapport can also sell up to $150.0 million of stock through an at-the-market program, though not for 30 days after the offering.⁵

In a liquidation the notes, as senior unsecured debt, rank ahead of the common stock, and the base prospectus showed no preferred stock outstanding as of March 6, 2026.¹ Net tangible book value was $8.81 a share at June 30, far below the $21.00 price.² Officers and directors are locked up for 90 days, certain holders for 45 days and the company for 30 days, though the lead banks can release them early.³

The raise follows the October 20 result in bipolar mania.¹ In a placebo-controlled trial of 253 adults treated for three weeks in hospital, scores on the Young Mania Rating Scale, which runs from 0 to 60, fell 15.4 points on RAP-219 versus 12.3 on placebo.² The 3.1-point gap had a p-value of 0.045, just inside the usual bar for statistical significance, and a doctor-rated secondary measure improved 0.4 points with a p-value of 0.024.³ No serious side effects were reported.⁴ The weak spot is who stayed in the trial: 24.6% of drug patients stopped treatment against 11.8% on placebo, mostly by withdrawing consent, 16.7% against 4.7%.⁵ Agitation, the most common side effect, hit 16.7% on drug versus 9.4% on placebo, and safety data from the eight-week follow-up are still to come.⁶ The stock closed at $29.32 on October 20 and at $25 a day later, a drop of about 15%.⁷

The bull case starts with cash. Once the deals settle on October 30, Rapport will have about $755.7 million on paper, its preliminary September 30 cash estimate plus net proceeds before fourth-quarter spending, against a recent burn of about $41 million a quarter, and even before the raise it said its cash reached beyond expected Phase 3 results in focal onset seizures.¹ The company expects that burn to rise: its second-quarter operating loss was $60.8 million, and it says expenses and operating losses will increase substantially.² Two late-stage epilepsy trials are enrolling, a Phase 3 trial in primary generalized tonic-clonic seizures is planned for the first half of 2027, and bipolar mania now has a positive placebo-controlled trial behind it.³ Directors bought after the data: Steven Paul paid $27.28 a share for 35,714 shares on October 22, and finance chief Troy Ignelzi bought 5,500 shares at $26.10 the day before, both above the $21.00 deal price.⁴

The bear case, strongest point first. The deal priced 23.7% below the last close and the conversion price sits under that close, so buyers demanded a deep discount, and the notes, new stock and options could add roughly half again to the share count.¹ The bipolar win was narrow, with high dropout on drug, and the Phase 3 design still needs the regulator's input.² The guided runway moved little despite the new money, which points to much higher spending, and the company has said it will need more funding to keep operating.³ The prospectus also expects note buyers to use a convertible arbitrage strategy, which means short selling the stock, adding selling pressure just as the new shares settle.⁴

Rapport's own plan, which is a set of goals and not results, runs as follows. It expects initial open-label data in focal onset seizures in the fourth quarter of 2026 and a meeting with the Food and Drug Administration on the bipolar data in the first quarter of 2027.¹ It plans a Phase 3 trial in primary generalized tonic-clonic seizures in the first half of 2027, two Phase 3 bipolar trials in the second half of 2027, and first data on a long-acting injection in the third quarter of 2027.²

From its last close before the filing, $25.31 on October 26, the stock rose 8.8% to $27.54 at the October 27 close, before the deal was priced at $21.00.¹ We expect a close above $21.00 on the first trading day after settlement, because the stock closed at $27.54 the day before pricing and, after the data, director Steven Paul paid $27.28 a share and finance chief Troy Ignelzi paid $26.10.² Against that, short selling by note buyers who hedge, the slide from $42.74 in mid-September and the $25 close on October 21 show the stock could still sink toward the deal price.³ What would prove the bull case wrong: the stock closing below the $21.00 deal price soon after settlement on October 30, a third-quarter report showing cash well under $395.0 million, or regulators asking for more in the 2027 meeting.⁴

The filings and releases call the private buyer only a certain investor, so we do not know who is putting in $30.0 million or whether it already owns shares.

The October 28 pricing release still says holders can convert before September 1, 2032 only if conditions are met, and that Rapport may settle in cash, shares or both.¹ The term sheet says those conditions are gone and settlement is shares only, and we follow the term sheet until the final prospectus supplement is filed.²

The $395.0 million is a preliminary estimate, and actual third-quarter results will come only after the offering, so the quarter's loss and spending are not known yet.

No filing breaks out what the Phase 3 programs will cost, or why the runway only moves from the second half of 2029 to the end of 2029.

Rapport plans to discuss the data and the trial design with the Food and Drug Administration in the first quarter of 2027, and no filing says what the agency thinks.